Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 4:57 pm Unchanged |
2021-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA |
ORBIMED ADVISORS LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-11 4:51 pm Purchase |
2021-12-31 | 13G | VectivBio Holding AG VECT |
ORBIMED ADVISORS LLC | 4,903,504 14.000% |
73,500 (+1.52%) |
Filing History |
| 2022-02-11 4:49 pm Sale |
2021-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
ORBIMED ADVISORS LLC | 5,456,780 7.400% |
-87,432 (-1.58%) |
Filing History |
| 2022-02-11 4:48 pm Sale |
2021-12-31 | 13G | Strongbridge Biopharma plc SBBP |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,986,869 (Position Closed) |
Filing History |
| 2022-02-11 4:46 pm Purchase |
2021-12-31 | 13G | Sonendo, Inc. SONX |
ORBIMED ADVISORS LLC | 49 7.500% |
49 (New Position) |
Filing History |
| 2022-02-11 4:42 pm Purchase |
2021-12-31 | 13G | RxSight, Inc. RXST |
ORBIMED ADVISORS LLC | 1,062,500 3.900% |
1,062,500 (New Position) |
Filing History |
| 2022-02-11 4:40 pm Purchase |
2021-12-31 | 13G | Protara Therapeutics, Inc. TARA |
ORBIMED ADVISORS LLC | 671,741 6.000% |
671,741 (New Position) |
Filing History |
| 2022-02-11 4:39 pm Sale |
2021-12-31 | 13G | PANDION THERAPEUTICS INC PAND |
ORBIMED ADVISORS LLC | 0 0.000% |
-1,040,825 (Position Closed) |
Filing History |
| 2022-02-11 4:38 pm Sale |
2021-12-31 | 13G | Otonomy, Inc. OTIC |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,480,800 (Position Closed) |
Filing History |
| 2022-02-11 4:35 pm Unchanged |
2021-12-31 | 13G | NeuroPace, Inc. NPCE |
ORBIMED ADVISORS LLC | 4,012,281 16.500% |
0 (Unchanged) |
Filing History |
| 2022-02-11 4:31 pm Purchase |
2021-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 6,063,345 5.590% |
1,544,989 (+34.19%) |
Filing History |
| 2022-02-11 4:30 pm Sale |
2021-12-31 | 13G | MeiraGTx Holdings plc MGTX |
ORBIMED ADVISORS LLC | 3,593,966 8.100% |
-375,459 (-9.46%) |
Filing History |
| 2022-02-11 4:29 pm Sale |
2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR |
ORBIMED ADVISORS LLC | 0 0.000% |
-732,323 (Position Closed) |
Filing History |
| 2022-02-11 4:27 pm Purchase |
2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
ORBIMED ADVISORS LLC | 2,200,200 4.300% |
2,200,200 (New Position) |
Filing History |
| 2022-02-11 4:26 pm Purchase |
2021-12-31 | 13G | Harpoon Therapeutics, Inc. HARP |
ORBIMED ADVISORS LLC | 166,790 5.100% |
64,720 (+63.41%) |
Filing History |
| 2022-02-11 4:23 pm Sale |
2021-12-31 | 13G | Gracell Biotechnologies Inc. GRCL |
ORBIMED ADVISORS LLC | 5,970,672 8.900% |
-23,882,692 (-80.00%) |
Filing History |
| 2022-02-11 4:22 pm Sale |
2021-12-31 | 13G | Forte Biosciences, Inc. FBRX |
ORBIMED ADVISORS LLC | 0 0.000% |
-25,431 (Position Closed) |
Filing History |
| 2022-02-11 4:21 pm Sale |
2021-12-31 | 13G | Standard BioTools Inc. LAB |
ORBIMED ADVISORS LLC | 3,416,871 4.460% |
-82,375 (-2.35%) |
Filing History |
| 2022-02-11 4:19 pm Purchase |
2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 3,196,876 6.700% |
443,309 (+16.10%) |
Filing History |
| 2022-02-11 4:18 pm Purchase |
2021-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
ORBIMED ADVISORS LLC | 3,424 4.300% |
3,424 (New Position) |
Filing History |